Boston (1)

Duarte (1)

Houston (1)

Palo Alto (1)

Tampa (1)

Refractory Diffuse Large B Cell Lymphoma (1)

Active, not recruiting (1)

phase 1/phase 2 (1)

Kite, A Gilead Company (1)

Genentech, Inc. (1)

atezolizumab (1)

cyclophosphamide (1)

fludarabine (1)

kte-c19 (1)

biological (1)

drug (1)

Industry (1)

Interventional (1)

refractory diffuse large b cell lymphoma

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Apr 27, 2022